Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 2/2020

01-02-2020 | Ampicillin | Understanding the Disease

Understanding resistance in enterococcal infections

Authors: Jordi Rello, Laura Campogiani, Vandana Kalwaje Eshwara

Published in: Intensive Care Medicine | Issue 2/2020

Login to get access

Excerpt

In the World Health Organization global pathogen priority list, vancomycin-resistant enterococci (VRE) were ranked high-priority pathogens, identifying multidrug resistant (MDR) enterococci as an important threat [1]. Enterococcus faecalis and Enterococcus faecium have complex susceptibility profiles and can cause infections in critically ill patients. …
Appendix
Available only for authorised users
Literature
1.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318–327CrossRef
2.
Faron ML, Ledeboer NA, Buchan BW (2016) Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant enterococcus in the health care setting. J Clin Microbiol 54(10):2436–2447CrossRef
3.
4.
Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, Hammerum AM, Schaffer K, Burns K, Murchan S, Novais C, Freitas AR, Peixe L, Del Grosso M, Pantosti A, Werner G (2018) Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 40:25–39
5.
De Angelis G, Cataldo MA, De Waure C, Venturiello S, La Torre G, Cauda R, Carmeli Y, Tacconelli E (2014) Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. J Antimicrob Chemother 69(5):1185–1192CrossRef
6.
Nigo M, Munita JM, Arias CA, Murray BE (2014) What’s new in the treatment of enterococcal endocarditis? Curr Infect Dis Rep 16(10):431CrossRef
7.
Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ (2015) β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 70(6):1738–1743PubMedPubMedCentral
8.
Miller WR, Murray BE, Rice LB, Arias CA (2016) Vancomycin-resistant enterococci: therapeutic challenges in the 21st century. Infect Dis Clin N Am 30(2):415–439CrossRef
9.
Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, Chang PK, O’Neill PJ, Mollen KP, Huston JM, Diaz JJ Jr, Prince JM (2017) The surgical infection society revised guidelines on the management of intra-abdominal infection. Surg Infect 18(1):1–76CrossRef
10.
Kanjilal S, Kalil AC, Klompas M (2018) What is the best treatment for vancomycin-resistant enterococcal bloodstream infections? Crit Care Med 46(10):1700–1703CrossRef
11.
Shukla BS, Shelburne S, Reyes K, Kamboj M, Lewis JD, Rincon SL, Reyes J, Carvajal LP, Panesso D, Sifri CD, Zervos MJ, Pamer EG, Tran TT, Adachi J, Munita JM, Hasbun R, Arias CA (2016) Influence of minimum inhibitory concentration in clinical outcomes of enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint? Clin Infect Dis 62(12):1514–1520CrossRef
12.
Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL (2018) A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis 67(2):303–309CrossRef
13.
Baddour M, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Tauberti KA, on behalf of the American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council (2015) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation 132(15):1435–1486CrossRef
Metadata
Title
Understanding resistance in enterococcal infections
Authors
Jordi Rello
Laura Campogiani
Vandana Kalwaje Eshwara
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 2/2020
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-019-05875-9

Other articles of this Issue 2/2020

Intensive Care Medicine 2/2020 Go to the issue

Editorial

A microbiologist consultant should attend daily ICU rounds

Conference Reports and Expert Panel

Bloodstream infections in critically ill patients: an expert statement

What's New in Intensive Care

Antibiotic prophylaxis in the ICU: to be or not to be administered for patients undergoing procedures?

Narrative Review

Critical care management of adults with community-acquired severe respiratory viral infection

Narrative Review

Severe flu management: a point of view

Editorial

Clinical management of sepsis can be improved by artificial intelligence: yes